Anika Works Through Distributor Disruptions in Solid Second Quarter

Anika Therapeutics reported 2Q22 orthopedic sales of $37.8 million, +4.5% compared to 2Q21.

The company benefitted from favorable order timing both in the U.S. and internationally for its orthobiologics products. Anika expects lower revenues for this line in the second half of the year.

Joint preservation and restoration products faced...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us